Dig Dis Sci

Background Guidelines for the treatment of HCV-infected persons were updated in August 2015 with new recommendations for patients with renal impairment. Treatment is imperative for patients with severe, renal-associated extrahepatic manifestations of HCV infection. Aims We sought to describe the prevalence of these conditions among current HCV-infected patients in a population-based prospective, observational cohort study at four large US health systems. Methods Data from cohort patients with chronic HCV infection during 2012 were analyzed for the period from 2006–2013. We determined the prevalence of mild-moderately impaired renal function defined as having the most recent estimated glomerular filtration rate [eGFR] <80 ml/min/1.73m2, with severe impairment defined as eGFR<30 ml/min/1.73m2, based on the treatment guidelines. Prevalence of extrahepatic conditions were ascertained using ICD9-codes. Results Among 5,772 persons the prevalence of eGFR<80 was 33% and eGFR<30 was 2%, including among patients with hepatic fibrosis. Diagnosed extrahepatic renal manifestations were rare: vasculitis- 0.2%, nephrotic syndrome- 0.3%, and cryoglobulinemia- 0.9%. Conclusions While the prevalence of severe renal impairment and diagnosed extrahepatic manifestations were low, mild-to-moderate renal impairment was common in HCV patients, including those with advanced liver fibrosis for whom the need for treatment is urgent.

27216163

PMC5675517

Journal Article

CDC Public Access